PRF1 and neoplasm: CAR T-cells are genetically modified T-cells expressing chimeric-antigen receptor that enables them to specifically recognize and bind the target tumor antigen (e.g., CD19) followed by cytotoxic elimination of the tumor cells via perforin/granzyme-induced apoptosis (Figure 1).